Targeted Drugs for Allergic Diseases Market Set to Hit USD 30.22 Billion by 2034, Driven by Rising Allergic Disorders The global targeted drugs for allergic diseases market size was valued at USD 13.96 billion in 2024 and is predicted to hit around USD 30.22 billion by 2034, rising at a 8.06% CAGR, a study published […]

American Rebel Holdings, Inc. (NASDAQ: AREB) Adds C & C Distributors to Advance American Rebel Light Beer's Distribution-First Growth Strategy in Arkansas GlobeNewswire December 01, 2025 Family-owned Anheuser-Busch wholesaler extends American Rebel Light's patriotic footprint across northeast Arkansas with deep local relationships, high-volume channel access, and a 30+ year track record of brand building NASHVILLE,

Tokyo Lifestyle Announces Strategic Investment Partnership to Accelerate Expansion in Hong Kong and Australia GlobeNewswire December 01, 2025 Tokyo, Japan, Dec. 01, 2025 (GLOBE NEWSWIRE) — Tokyo Lifestyle Co., Ltd. (“Tokyo Lifestyle” or the “Company”) (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, collectible cards,

PodcastOne And Dr. Phil's Envoy Media Co. Join Forces To Launch New Television, DTC and Podcast Based Original and Owned Content Network, Led By All New Daily Dr. Phil Podcast GlobeNewswire December 01, 2025 Premieres to Over 125 Million Pay Cable Subscribers and Free Streaming Viewers Via Envoy TV and Envoy FAST Channels, Dr. Phil

Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025 GlobeNewswire December 01, 2025 ROCKVILLE, Md. and SUZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company“), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel,

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study GlobeNewswire December 01, 2025 Salarius subsidiary Decoy Therapeutics' influenza fusion inhibitors, designed using its proprietary IMP3ACT(TM) platform, show excellent in silico free energy binding to the viral target entry protein, supporting potential for anti-flu activity IMP3ACT's demonstrated capability to create a single

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions GlobeNewswire December 01, 2025 BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) — Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following

Fancamp Announces Spin-Out of Mineral Exploration Assets and Creation of Goldera Exploration GlobeNewswire December 01, 2025 VANCOUVER, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) — Fancamp Exploration Ltd. (“Fancamp” or the “Corporation“) (TSX Venture Exchange: FNC) is pleased to announce that its Board of Directors (the “Fancamp Board“) has unanimously approved a strategic reorganization of

Cerence AI to Participate in Raymond James TMT and Consumer Conference GlobeNewswire December 01, 2025 BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”), a global leader pioneering conversational AI-powered user experiences, today announced that the Company will participate in the Raymond James TMT and Consumer Conference on Monday, December

Peer To Peer Network Releases Q&A Call Summary Regarding Launch of PTOP Intelligence Labs GlobeNewswire December 01, 2025 CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) — Peer To Peer Network (OTC: PTOP) today issued a summary of its November 27th investor call, where newly appointed division president Derek McCarthy outlined the Company's AI-driven strategy for